Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals plc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DUBLIN, AUG. 07, 2025 (GLOBE NEWSWIRE) -- AVADEL PHARMACEUTICALS PLC (NASDAQ: AVDL), A COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF AVADEL'S BOARD OF DIRECTORS APPROVED THE GRANT OF NON-STATUTORY OPTIONS TO EIGHT (8) NEW EMPLOYEES TO PURCHASE 60,400 ORDINARY SHARES UNDER AVADEL'S 2021 INDUCEMENT PLAN. THE AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE EMPLOYEE'S ACCEPTANCE OF EMPLOYMENT WITH AVADEL IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4). THE OPTIONS HAVE A TEN-YEAR TERM AND VEST OVER FOUR YEARS, WITH 25% VESTING ON THE ONE-YEAR ANNIVERSARY OF EACH NEW EMPLOYEE'S RESPECTIVE START DATE AND 25% VESTING ON THE SECOND, THIRD, AND FOURTH ANNIVERSARY THEREAFTER. THE OPTIONS ARE SUBJECT TO THE TERMS AND CONDITIONS OF AVADEL'S 2021 INDUCEMENT PLAN APPROVED BY THE BOARD OF DIRECTORS IN NOVEMBER 2021 AND THE TERMS AND CONDITIONS OF AWARD AGREEMENTS COVERING THE GRANTS.

AVADEL ANNOUNCES GRANT OF INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

-- GENERATED LUMRYZ NET REVENUE OF $68.1 MILLION, A 64% INCREASE COMPARED TO SECOND QUARTER 2024, NET INCOME OF $9.7 MILLION AND EARNINGS PER SHARE OF $0.10 -- -- 3,100 PATIENTS ON LUMRYZ AS OF JUNE 30, 2025, A 63% INCREASE COMPARED TO JUNE 30, 2024 -- -- RAISES 2025 FULL YEAR REVENUE GUIDANCE TO $265 - $275 MILLION -- -- RECEIVED ORPHAN DRUG DESIGNATION FROM FDA FOR LUMRYZ (SODIUM OXYBATE) FOR EXTENDED-RELEASE ORAL SUSPENSION FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) -- -- ON TRACK TO COMPLETE ENROLLMENT IN PIVOTAL PHASE 3 REVITALYZ STUDY EVALUATING EFFICACY AND SAFETY OF LUMRYZ IN IH BY END OF 2025 -- -- AVADEL MANAGEMENT TO HOST CONFERENCE CALL TODAY AT 8:30 A.M. ET -- DUBLIN, IRELAND, AUG. 07, 2025 (GLOBE NEWSWIRE) -- AVADEL PHARMACEUTICALS PLC (NASDAQ: AVDL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES, TODAY INCREASED ITS REVENUE GUIDANCE FOR THE YEAR AS IT ANNOUNCED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025.

AVADEL PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND RAISES 2025 REVENUE GUIDANCE

DUBLIN, IRELAND, JULY 31, 2025 (GLOBE NEWSWIRE) -- AVADEL PHARMACEUTICALS PLC (NASDAQ: AVDL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES, ANNOUNCED TODAY THAT IT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST AT 8:30 A.M. ET ON THURSDAY, AUGUST 7, 2025, TO PROVIDE A CORPORATE UPDATE AND DISCUSS THE COMPANY'S FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025.

AVADEL PHARMACEUTICALS TO PROVIDE A CORPORATE UPDATE AND REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 7

DUBLIN, JULY 21, 2025 (GLOBE NEWSWIRE) -- AVADEL PHARMACEUTICALS PLC (NASDAQ: AVDL), A COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF AVADEL'S BOARD OF DIRECTORS APPROVED THE GRANT OF NON-STATUTORY OPTIONS TO SIX (6) NEW EMPLOYEES TO PURCHASE 34,200 ORDINARY SHARES UNDER AVADEL'S 2021 INDUCEMENT PLAN. THE AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE EMPLOYEE'S ACCEPTANCE OF EMPLOYMENT WITH AVADEL IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4). THE OPTIONS HAVE A TEN-YEAR TERM AND VEST OVER FOUR YEARS, WITH 25% VESTING ON THE ONE-YEAR ANNIVERSARY OF EACH NEW EMPLOYEE'S RESPECTIVE START DATE AND 25% VESTING ON THE SECOND, THIRD, AND FOURTH ANNIVERSARY THEREAFTER. THE OPTIONS ARE SUBJECT TO THE TERMS AND CONDITIONS OF AVADEL'S 2021 INDUCEMENT PLAN APPROVED BY THE BOARD OF DIRECTORS IN NOVEMBER 2021 AND THE TERMS AND CONDITIONS OF AWARD AGREEMENTS COVERING THE GRANTS.

GREENWICH, CONN. & CHESTERFIELD, MO.--(BUSINESS WIRE)--ASL STRATEGIC VALUE FUND, LP (TOGETHER WITH ITS AFFILIATES, ASL STRATEGIC VALUE FUND OR WE), A SIGNIFICANT SHAREHOLDER OF AVADEL PHARMACEUTICALS PLC (NASDAQ: AVDL) (AVADEL OR THE COMPANY), TODAY ISSUED AN OPEN LETTER CALLING ON AVADEL'S SHAREHOLDERS TO VOTE AGAINST ALL OF THE COMPANY'S DIRECTOR NOMINEES UP FOR ELECTION AT THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS SCHEDULED FOR JULY 29, 2025 (THE ANNUAL MEETING). THE FULL TEX.

ASL STRATEGIC VALUE FUND ISSUES OPEN LETTER TO AVADEL SHAREHOLDERS

DUBLIN, JUNE 30, 2025 (GLOBE NEWSWIRE) -- AVADEL PHARMACEUTICALS PLC (NASDAQ: AVDL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES, ANNOUNCED THAT, ON FRIDAY, JUNE 27, 2025, THE U.S. COURT OF APPEALS FOR THE DISTRICT OF COLUMBIA CIRCUIT (THE APPEALS COURT) AFFIRMED A PRIOR DECISION OF THE U.S. DISTRICT COURT FOR THE DISTRICT OF COLUMBIA (THE DISTRICT COURT) IN FAVOR OF THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) IN A SUIT BROUGHT BY JAZZ PHARMACEUTICALS INC. (JAZZ) REGARDING THE FDA'S APPROVAL OF LUMRYZTM, THE FIRST AND ONLY ONCE-AT-BEDTIME OXYBATE TREATMENT FOR CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY.

AVADEL PHARMACEUTICALS ANNOUNCES UNANIMOUS APPEALS COURT DECISION UPHOLDING FDA APPROVAL OF LUMRYZ IN NARCOLEPSY IN ADMINISTRATIVE PROCEDURE ACT LITIGATION

DUBLIN, JUNE 16, 2025 (GLOBE NEWSWIRE) -- AVADEL PHARMACEUTICALS PLC (NASDAQ: AVDL), A COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF AVADEL'S BOARD OF DIRECTORS APPROVED THE GRANT OF NON-STATUTORY OPTIONS TO TWO NEW EMPLOYEES TO PURCHASE 9,600 ORDINARY SHARES UNDER AVADEL'S 2021 INDUCEMENT PLAN. IN ADDITION, EFFECTIVE AS OF MAY 13, 2025, THE COMPENSATION COMMITTEE OF AVADEL'S BOARD OF DIRECTORS APPROVED A GRANT OF NON-STATUTORY OPTIONS TO SUSAN RODRIGUEZ, AVADEL'S NEWLY APPOINTED CHIEF OPERATING OFFICER, TO PURCHASE 300,000 ORDINARY SHARES UNDER AVADEL'S 2021 INDUCEMENT PLAN.

DUBLIN, JUNE 05, 2025 (GLOBE NEWSWIRE) -- AVADEL PHARMACEUTICALS PLC (NASDAQ: AVDL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES, ANNOUNCED TODAY THAT LUMRYZTMHAS BEEN GRANTED ORPHAN DRUG DESIGNATION (ODD) FROM THE U.S. FOOD & DRUG ADMINISTRATION (FDA) FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH). SPECIFICALLY, ODD WAS GRANTED BASED ON THE PLAUSIBLE HYPOTHESIS THAT LUMRYZ MAY BE CLINICALLY SUPERIOR TO THE SAME DRUG(S) ALREADY APPROVED FOR THE SAME INDICATION, BECAUSE LUMRYZ MAY PROVIDE A MAJOR CONTRIBUTION TO PATIENT CARE DUE TO ITS ONCE-NIGHTLY DOSING FOR PATIENTS WITH IH, A CHRONIC SLEEP DISORDER THAT REQUIRES POTENTIALLY LIFELONG TREATMENT.

AVADEL PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR LUMRYZ (SODIUM OXYBATE) FOR EXTENDED-RELEASE ORAL SUSPENSION FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA

 14 ABSTRACTS ACCEPTED, INCLUDING FOUR ORAL PRESENTATIONS   INTERIM ANALYSIS OF REAL-WORLD REFRESH STUDY DEMONSTRATED CLINICALLY SIGNIFICANT EFFICACY AND IMPROVEMENT OF EDS FOR PATIENTS WHO SWITCHED FROM TWICE-NIGHTLY OXYBATE TO ONCE-AT-BEDTIME LUMRYZ   DATA REFLECTING THE THERAPEUTIC RESULTS OF LUMRYZ TREATMENT IN PEOPLE WITH NARCOLEPSY ACROSS CLINICAL AS WELL AS REAL-WORLD SETTINGS WILL BE PRESENTED  DUBLIN, IRELAND, MAY 29, 2025 (GLOBE NEWSWIRE) -- AVADEL PHARMACEUTICALS PLC (NASDAQ: AVDL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES, TODAY ANNOUNCED THAT NEW DATA SUPPORTING THE USE OF LUMRYZ AS A NARCOLEPSY TREATMENT AND ADDITIONAL DATA TO BETTER UNDERSTAND THE REAL-LIFE EXPERIENCE OF PEOPLE LIVING WITH NARCOLEPSY WILL BE PRESENTED IN FOUR ORAL PRESENTATIONS AND 14 POSTERS AT SLEEP 2025, THE 39TH ANNUAL MEETING OF THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES (APSS), TAKING PLACE JUNE 8-11, 2025 IN SEATTLE. POST-HOC ANALYSIS OF THE PIVOTAL PHASE 3 REST-ON CLINICAL TRIAL, RESTRICTED TO THOSE STUDY PARTICIPANTS WITH THE MOST SEVERE SLEEPINESS AT BASELINE AS MEASURED BOTH OBJECTIVELY AND SUBJECTIVELY, SHOWED LUMRYZ PARTICIPANTS WITH A MEDIAN EPWORTH SLEEPINESS SCALE (ESS) SCORE AT WEEK 13 THAT WAS IMPROVED TO THE RANGE AT OR BELOW THAT CONSIDERED NORMAL.

Avadel Pharmaceuticals plc

AVDL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Avadel Pharmaceuticals plc

AVDL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AVDL